EA201992413A1 - Противогрибковые средства, используемые в комбинации - Google Patents

Противогрибковые средства, используемые в комбинации

Info

Publication number
EA201992413A1
EA201992413A1 EA201992413A EA201992413A EA201992413A1 EA 201992413 A1 EA201992413 A1 EA 201992413A1 EA 201992413 A EA201992413 A EA 201992413A EA 201992413 A EA201992413 A EA 201992413A EA 201992413 A1 EA201992413 A1 EA 201992413A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
antifungal
agents
enfumafungin
agents used
Prior art date
Application number
EA201992413A
Other languages
English (en)
Russian (ru)
Inventor
Давид А. Ангуло Гонсалес
Original Assignee
Сайнексис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайнексис, Инк. filed Critical Сайнексис, Инк.
Publication of EA201992413A1 publication Critical patent/EA201992413A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EA201992413A 2017-04-10 2018-04-04 Противогрибковые средства, используемые в комбинации EA201992413A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483647P 2017-04-10 2017-04-10
PCT/US2018/026088 WO2018191077A1 (en) 2017-04-10 2018-04-04 Antifungal agents used in combination

Publications (1)

Publication Number Publication Date
EA201992413A1 true EA201992413A1 (ru) 2020-03-16

Family

ID=62063223

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992413A EA201992413A1 (ru) 2017-04-10 2018-04-04 Противогрибковые средства, используемые в комбинации

Country Status (13)

Country Link
US (2) US11110102B2 (cg-RX-API-DMAC7.html)
EP (1) EP3609539A1 (cg-RX-API-DMAC7.html)
JP (2) JP7263313B2 (cg-RX-API-DMAC7.html)
KR (1) KR102683355B1 (cg-RX-API-DMAC7.html)
CN (1) CN110769854B (cg-RX-API-DMAC7.html)
AR (1) AR113221A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018253031B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059225A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992413A1 (cg-RX-API-DMAC7.html)
MA (1) MA49889A (cg-RX-API-DMAC7.html)
MX (1) MX2019012116A (cg-RX-API-DMAC7.html)
TW (1) TWI806861B (cg-RX-API-DMAC7.html)
WO (1) WO2018191077A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3661503T3 (pl) * 2017-08-04 2023-01-09 Scynexis, Inc. Środki przeciwgrzybicze o zwiększonej aktywności przy kwasowym odczynie ph
AU2020228036B2 (en) * 2019-02-27 2025-08-07 Scynexis, Inc. Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
WO2010019204A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
BRPI0912074B1 (pt) * 2008-08-12 2021-08-03 Merck Sharp & Dohme Corp Composto e composição farmacêutica
PL3221308T3 (pl) * 2014-11-21 2019-03-29 F2G Limited Środki przeciwgrzybicze
PT3247711T (pt) 2015-01-19 2022-05-16 Scynexis Inc Novos sais e polimorfos de scy-078

Also Published As

Publication number Publication date
JP7263313B2 (ja) 2023-04-24
WO2018191077A1 (en) 2018-10-18
AR113221A1 (es) 2020-02-19
EP3609539A1 (en) 2020-02-19
CN110769854A (zh) 2020-02-07
CN110769854B (zh) 2023-01-13
KR102683355B1 (ko) 2024-07-10
TW201842915A (zh) 2018-12-16
KR20190133251A (ko) 2019-12-02
US20180325919A1 (en) 2018-11-15
US20220202833A1 (en) 2022-06-30
JP2023030113A (ja) 2023-03-07
AU2018253031B2 (en) 2024-04-11
MX2019012116A (es) 2019-11-21
AU2018253031A1 (en) 2019-10-31
KR20240110109A (ko) 2024-07-12
BR112019021138A2 (pt) 2020-05-12
MA49889A (fr) 2020-06-24
TWI806861B (zh) 2023-07-01
JP2020513037A (ja) 2020-04-30
JP7574268B2 (ja) 2024-10-28
CA3059225A1 (en) 2018-10-18
US11110102B2 (en) 2021-09-07

Similar Documents

Publication Publication Date Title
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
EA202091506A1 (ru) Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
MX389697B (es) Nuevos derivados de pirazolopirimidina.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201991312A1 (ru) Комбинации активных соединений
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
MX2013012123A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida.
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MX2019005234A (es) Amidas y aminas de azol como inhibidores de integrina alfa v.
CY1120907T1 (el) Αντιμυκητιασικοι παραγοντες
CR20170268A (es) Combinaciones de compuestos activos
UY36432A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio) carboxamida y compuesto(s) fungicida(s)
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
EA201992509A1 (ru) Гетероарилфениламинохинолины и аналоги
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
MX2019012116A (es) Agentes antifungicos utilizados en combinacion.
EA201890854A1 (ru) Иминосоединения с 2-хлорпиримидин-5-ильным заместителем в качестве средств борьбы с вредителями
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2019014302A (es) Agente para prevenir o tratar la ataxia espinocerebelosa.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
MX381234B (es) Agente preventivo y/o terapéutico de enfermedad inmune.
PH12017501668A1 (en) Bace1 inhibitors
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
EA201791483A1 (ru) Фармацевтическая композиция для лечения микоза